转移性乳腺癌
乳腺癌
生物标志物
医学
癌症
雌激素受体
CA15-3号
肿瘤科
微卫星不稳定性
癌症研究
突变
转移
内科学
生物
基因
微卫星
遗传学
等位基因
作者
Geetha Jagannathan,Marissa J. White,Rena R. Xian,Leisha A. Emens,Ashley Cimino‐Mathews
标识
DOI:10.1016/j.cll.2023.03.004
摘要
Predictive biomarker testing on metastatic breast cancer is essential for determining patient eligibility for targeted therapeutics. The National Comprehensive Cancer Network currently recommends assessment of specific biomarkers on metastatic tumor subtypes, including hormone receptors , HER2 , and BRCA1/2 mutations, on all newly metastatic breast cancers subtypes; programmed death-ligand 1 on metastatic triple-negative carcinomas; and PIK3CA mutation status on estrogen receptor-positive carcinomas. In select circumstances mismatch repair protein deficiency and/or microsatellite insufficiency, tumor mutation burden, and NTRK translocation status are also testing options. Novel biomarker testing, such as detecting PIK3CA mutations in circulating tumor DNA , is expanding in this rapidly evolving arena.
科研通智能强力驱动
Strongly Powered by AbleSci AI